- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04078750
PLATO - Medication Adherence in Transplant Recipients
Pre-Transplant Multidisciplinary Assessment on Medication Adherence and Transplant Outcomes
A tanulmány áttekintése
Állapot
Beavatkozás / kezelés
Részletes leírás
Phase I - Control group.
- The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.
- Tacrolimus capsules (standard of care immunosupression medication) will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.
- Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) self-report questionnaire and Long-term Medication Behaviour Self-efficacy self-report Scale at 3 months after transplantation.
Phase II - Interventional Group.
I. Pre-transplant phase:
- Measurement of Adherence to Medications Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant. For patients who are lactose intolerance, they will be instructed to remove the correct number of capsules from the vials but there is no need to take the capsules. Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence.
Health literacy: Assessments to completed by the participant:
- Short Literacy Survey (SLS), a self-report 3 question survey, has been validated in kidney transplant recipients and shown to correlate well with the Rapid Estimate of Adult Literacy in Medicine (REALM) and the shortened Test of Functional Health Literacy in Adults (S-TOFHLA). The three questions are: 1) "How often do you have someone help you read hospital materials?"; 2) "How confident are you filling out medical forms by yourself?"; and 3) "How often do you have problems learning about your medical condition because of difficulty understanding written information?"
- Newest Vital Signs - transplant version (NVS-T) The original NVS consists of a prescription label with 6 questions that measures health literacy and numeracy skills but is not specific to any particular area of medicine. The modified transplant version consists of 2 prescription labels and has been validated. The first label is for an antibiotic, amoxicillin, and the second label is for a cream, fluocinolone acetonide. There are 3 questions for each label, and the number of correct answers correlates with a health literacy category.
- Cognition will be assessed using the Montreal Cognitive Assessment (MoCA), a 30-question screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
- Self-efficacy will be assessed using the Long-term Medication Behaviour Self-efficacy Scale, a 27-item questionnaire about skills related to medication use. It assesses the following themes regarding patient's self-efficacy: personal attributions (7 items), environmental factors (13 items), task-related and behavioral factors (7 items).
- Customized post-transplant care plan prior to transplantation The post-transplant team will devise a tailored care plan based on assessment findings and discussed with the patient and/or caregivers prior to transplant. The post-transplant care plans will be common to both transplant programs.
II. Post-transplant phase:
- The post-transplant team will implement the tailored care plan as discussed with patient and/or caregiver(s).
- Tacrolimus capsules will be dispensed in MEMS caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.
- Patients will be asked to complete BAASIS questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months.
Current standard of care does not include any element of pharmacy evaluation of a person's ability to follow medication regimens.
At the conclusion of the use of MEMS caps subjects in either group will return the MEMS caps to the pharmacists at a regularly scheduled follow-up appointment.This will not require an additional trip to the hospital.
Tanulmány típusa
Beiratkozás (Várható)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Marianna Leung, Pharm D
- Telefonszám: 7787887468
- E-mail: MLeung@providencehealth.bc.ca
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Breanna Riou-Green, BSc
- Telefonszám: 64708 6046822344
- E-mail: briougreen@providencehealth.bc.ca
Tanulmányi helyek
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 1Y6
- Toborzás
- St. Paul's Hospital
-
Kapcsolatba lépni:
- Marianna Leung, Pharm D
- Telefonszám: 7787887468
- E-mail: MLeung@providencehealth.bc.ca
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Toborzás
- Vancouver General Hospital
-
Kapcsolatba lépni:
- Cindy Y Luo, Pharm D
- Telefonszám: 6043414264
- E-mail: Cindy.Luo@vch.ca
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Kidney transplant candidates anticipated to undergo transplantation from a deceased or living donor within 6 months of enrolment
Exclusion Criteria:
- There are no exclusion criteria. All eligible patients will be approached by a research assistant. Patients with limited English language fluency will be asked to participate with the assistance of a translator.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Sham Comparator: Phase I. Control group
|
Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
|
Kísérleti: Phase II. Intervention group
Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial.
Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules.
MEMS® is designed to record the date/time of opening and closure of the drug vial.
Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day.
Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence.
Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
|
Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
Időkeret: 3 month duration
|
Adherence is defined as patient opening the MEMS caps within 1 hour of dosing times (ie no missed doses AND ≤ 1-hour variations to scheduled dosing times).
Assumption will be made that patient has taken the correct tacrolimus dose if he or she opens MEMS caps within predefined dosing times.
Using the MEMS recorded electronic dosing history, a daily binary adherence rate will be calculated per patient (ie day with correct dosing and/or timing).
It is recognized that adherence rate may wane over time post-transplant.
A 3-month duration is chosen for the primary outcome for logistical reasons since out-of-town patients are usually transferred back to a peripheral transplant center closer to home at this time.
A pilot will be conducted for 40 local transplant recipients (20 each in control and interventional groups) to extend the use of MEMS for 6 months to capture any differences in adherence rates beyond three months.
|
3 month duration
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Self-reported adherence rates as measured by BAASIS
Időkeret: 3-12 months
|
Patients will be asked by research assistant to complete BAASIS questionnaire at 3 months after transplant (may be a phone call if patients are transferred to peripheral centers before 3 months).
|
3-12 months
|
The coefficient of variation (CV) of tacrolimus trough levels
Időkeret: 3-12 months
|
The coefficient of variation (CV) of tacrolimus trough levels at 3 months and at 12 months will be assessed.
We will compare the proportion of patients with CV ≥ 30% at 3 months and at 12 months.
The 12-month measurement will be assessed in all patients including patients who receive care in peripheral transplant centers as this information is readily accessible in our electronic records.
These measures will also help to address the long-term durability of any change in adherence related to the interventions.
|
3-12 months
|
Proportion of patients within target tacrolimus trough levels
Időkeret: 3-12 months
|
Proportion of patients within target tacrolimus trough levels at 3 months and at 12 months.
|
3-12 months
|
Comparison of post-transplant test results between intervention and control group
Időkeret: 3 months
|
Comparison of post-transplant test results between intervention and control group using a Long-term Medication Behaviour Self-efficacy Scale. The scale has 5 possible answers that reflect the extent that the participant is able to take their medications correctly in the described situations.
|
3 months
|
Medication Behaviour for intervention group only
Időkeret: 3 months
|
Comparison of post-transplant test results between intervention and control group using a Long-term Medication Behaviour Self-efficacy Scale. The scale has 5 possible answers that reflect the extent that the participant is able to take their medications correctly in the described situations.
|
3 months
|
Staff resource utilization
Időkeret: Through study completion, an average of 1 year
|
Time spent with patient education + re-education + discharge planning + resolving medication errors + arranging for medication management.
The post-transplant team will receive an inservice to ensure accurate and complete documentation of their time spent on the above activities.
|
Through study completion, an average of 1 year
|
Medication nonadherence-related hospital readmissions
Időkeret: 12 months
|
Medication nonadherence-related hospital readmissions will be assessed for 12 months after transplantation by review of all hospitalization records.
|
12 months
|
Biopsy proven acute rejection (BPAR) rate
Időkeret: 12 months
|
Biopsy proven acute rejection (BPAR) rate at 12 months
|
12 months
|
Kidney allograft function
Időkeret: 12 months
|
Kidney allograft function (SCr, UACR) at 12 months
|
12 months
|
Kidney allograft survival
Időkeret: 12 months
|
Kidney allograft survival at 12 months
|
12 months
|
Patient survival
Időkeret: 12 months
|
Patient survival at 12 months
|
12 months
|
Health Literacy for intervention group only
Időkeret: 3 months
|
This group will also undergo health literacy surveys which associates answers with values of 1-5: A lower score indicates lower health literacy.
|
3 months
|
Montreal Cognitive Assessment for intervention group only
Időkeret: 3 months
|
Cognition will be assessed using the Montreal Cognitive Assessment (MoCA), a 30-question screening instrument for mild cognitive dysfunction.
It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
|
3 months
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Marianna Leung, Pharm D, St. Paul's Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Várható)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- H19-02030
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .